Literature DB >> 8764934

Effect of interferon therapy on bile duct inflammation in hepatitis C.

B F Banner1, C Allan, L Smith, L Savas, H L Bonkovsky.   

Abstract

Inflammation of the bile ducts was studied in liver biopsies from patients with chronic hepatitis C to determine whether the frequency of inflamed bile ducts changes with therapy and correlates with other histological variables and expression of class I and II MHC antigens on ductal epithelium. Twenty patients treated at UMMC between 1991 and 1994 underwent needle biopsies of the liver before and after therapy with interferon alpha 2B (IFN). A complete response to therapy was defined as a return to normal serum alanine aminotransferase levels occurring and persisting during therapy. The number of inflamed bile ducts/total ducts (%IBDs), presence of piecemeal necrosis and lymphoid aggregates, and grade of inflammation were assessed in each high-power field in all areas with bile ducts. The frequencies of these variables were compared in cirrhotics and non-cirrhotics and in patients with complete or incomplete responses to IFN. Frozen sections of biopsies from 5 patients were immunostained using antibodies to HLA-DR and B-2 microglobulin, and positive staining was noted on bile ducts. Before therapy, the %IBD was slightly greater in patients with cirrhosis. After IFN, both %IBD and serum alkaline phosphatase levels decreased in non-cirrhotics who responded to IFN. The change in frequency of IBD with IFN paralleled the changes in the other histological features. No correlation was noted between bile duct inflammation and expression of class I and II antigens. The conclusion is that inflammation of the bile ducts occurs frequently in chronic hepatitis C, correlates with other features of inflammation in the triads, and decreases in response to IFN therapy.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8764934     DOI: 10.1007/bf00196698

Source DB:  PubMed          Journal:  Virchows Arch        ISSN: 0945-6317            Impact factor:   4.064


  22 in total

1.  Histological outcome in interferon alpha-2b treated patients with chronic posttransfusion non-A, non-B hepatitis.

Authors:  R Schvarcz; H Glaumann; O Weiland; G Norkrans; R Wejstål; A Frydén
Journal:  Liver       Date:  1991-02

2.  Abnormal bile duct epithelium in chronic aggressive hepatitis and cirrhosis. A review of morphology and clinical, biochemical, and immunologic features.

Authors:  H Poulsen; P Christoffersen
Journal:  Hum Pathol       Date:  1972-06       Impact factor: 3.466

3.  Expression of MHC products by normal and abnormal bile duct epithelium.

Authors:  J J Van den Oord; R Sciot; V J Desmet
Journal:  J Hepatol       Date:  1986       Impact factor: 25.083

Review 4.  Chronic hepatitis: morphology and nomenclature.

Authors:  K G Ishak
Journal:  Mod Pathol       Date:  1994-08       Impact factor: 7.842

5.  Treatment of chronic hepatitis C with recombinant interferon alfa. A multicenter randomized, controlled trial.

Authors:  G L Davis; L A Balart; E R Schiff; K Lindsay; H C Bodenheimer; R P Perrillo; W Carey; I M Jacobson; J Payne; J L Dienstag
Journal:  N Engl J Med       Date:  1989-11-30       Impact factor: 91.245

6.  Recombinant interferon alfa therapy for chronic hepatitis C. A randomized, double-blind, placebo-controlled trial.

Authors:  A M Di Bisceglie; P Martin; C Kassianides; M Lisker-Melman; L Murray; J Waggoner; Z Goodman; S M Banks; J H Hoofnagle
Journal:  N Engl J Med       Date:  1989-11-30       Impact factor: 91.245

7.  Hepatitic bile duct injuries in chronic hepatitis C: histopathologic and immunohistochemical studies.

Authors:  K Kaji; Y Nakanuma; M Sasaki; M Unoura; K Kobayashi; A Nonomura; K Tsuneyama; J Van de Water; M E Gershwin
Journal:  Mod Pathol       Date:  1994-12       Impact factor: 7.842

8.  Sensitivity, specificity, and predictability of biopsy interpretations in chronic hepatitis.

Authors:  A J Czaja; H A Carpenter
Journal:  Gastroenterology       Date:  1993-12       Impact factor: 22.682

9.  Pathological diagnosis of chronic hepatitis C: a multicenter comparative study with chronic hepatitis B. The Hepatitis Interventional Therapy Group.

Authors:  J H Lefkowitch; E R Schiff; G L Davis; R P Perrillo; K Lindsay; H C Bodenheimer; L A Balart; T J Ortego; J Payne; J L Dienstag
Journal:  Gastroenterology       Date:  1993-02       Impact factor: 22.682

10.  Histologic changes in liver biopsy specimens produced by recombinant interferon alpha-2b therapy for chronic non-A,non-B viral hepatitis. A randomized controlled trial.

Authors:  E David; A Pucci; D Palladin; G Saracco; E Garello; C Pintus; G Rocca; L Chiandussi; A Solinas; F Mollo
Journal:  Am J Clin Pathol       Date:  1992-10       Impact factor: 2.493

View more
  4 in total

1.  Alkaline phosphatase predicts relapse in chronic hepatitis C patients with end-of-treatment response.

Authors:  Gerd Bodlaj; Rainer Hubmann; Karim Saleh; Tatjana Stojakovic; Georg Biesenbach; Jörg Berg
Journal:  World J Gastroenterol       Date:  2010-05-21       Impact factor: 5.742

2.  HLA-A33/B44/DR6 is highly related to intrahepatic cholestasis induced by tiopronin.

Authors:  M Kurosaki; H Takagi; M Mori
Journal:  Dig Dis Sci       Date:  2000-06       Impact factor: 3.199

3.  Cholestatic presentation of chronic hepatitis C: a clinical and histological study with a review of the literature.

Authors:  K S Kumar; M H Saboorian; W M Lee
Journal:  Dig Dis Sci       Date:  2001-10       Impact factor: 3.199

4.  Chronic hepatitis C and autoimmune cholangitis: a case study and literature review.

Authors:  Pilar Sánchez-Pobre; Carmen Gonzalez; Estela Paz; Francisco Colina; Gregorio Castellano; Teresa Muñoz-Yague; Sarbelio Rodriguez; Carmen Yela; Victoria Alvarez; Ja Solís-Herruzo
Journal:  Dig Dis Sci       Date:  2002-06       Impact factor: 3.199

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.